TRKA (G595R)
Sign in to save this workspaceNTRK1 · Variant type: point · HGVS: p.G595R
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Repotrectinib | 99.1% | 0.9% | 84.21 |
| 2 | Ponatinib | 99.0% | 1.0% | 78.23 |
| 3 | Entrectinib | 81.3% | 18.7% | 93.69 |
| 4 | Cabozantinib | 68.5% | 31.5% | 92.73 |
| 5 | Darovasertib | 49.6% | 50.4% | 96.99 |
| 6 | Tivozanib | 34.7% | 65.3% | 92.42 |
| 7 | Ripretinib | 32.5% | 67.5% | 92.95 |
| 8 | Pralsetinib | 21.6% | 78.4% | 93.43 |
| 9 | Leniolisib | 19.7% | 80.3% | 100.00 |
| 10 | Umbralisib | 18.9% | 81.1% | 98.74 |
| 11 | Defactinib | 18.5% | 81.5% | 92.68 |
| 12 | Infigratinib | 17.1% | 82.9% | 98.24 |
| 13 | Pazopanib | 17.0% | 83.0% | 97.49 |
| 14 | Selumetinib | 16.1% | 83.9% | 100.00 |
| 15 | Apatinib | 11.8% | 88.2% | 97.73 |
| 16 | Binimetinib | 11.1% | 88.9% | 100.00 |
| 17 | Sunitinib | 9.1% | 90.9% | 91.73 |
| 18 | Ribociclib | 9.1% | 90.9% | 99.25 |
| 19 | Alpelisib | 8.9% | 91.1% | 97.22 |
| 20 | Capivasertib | 8.2% | 91.8% | 96.48 |
| 21 | Osimertinib | 7.9% | 92.1% | 97.24 |
| 22 | Trametinib | 7.9% | 92.1% | 99.50 |
| 23 | Alectinib | 7.9% | 92.1% | 95.49 |
| 24 | Pacritinib | 7.1% | 92.9% | 88.64 |
| 25 | Deucravacitinib | 6.7% | 93.3% | 98.99 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Repotrectinib | 99.1% | 98.9% | +0.2% |
| Ponatinib | 99.0% | 98.4% | +0.6% |
| Entrectinib | 81.3% | 99.0% | -17.7% |
| Cabozantinib | 68.5% | 93.6% | -25.0% |
| Darovasertib | 49.6% | — | — |
| Tivozanib | 34.7% | 85.7% | -50.9% |
| Ripretinib | 32.5% | 93.6% | -61.1% |
| Pralsetinib | 21.6% | 98.7% | -77.1% |
| Leniolisib | 19.7% | — | — |
| Umbralisib | 18.9% | — | — |
| Defactinib | 18.5% | 80.3% | -61.8% |
| Infigratinib | 17.1% | — | — |
| Pazopanib | 17.0% | — | — |
| Selumetinib | 16.1% | — | — |
| Apatinib | 11.8% | — | — |
| Binimetinib | 11.1% | — | — |
| Sunitinib | 9.1% | 82.8% | -73.6% |
| Ribociclib | 9.1% | — | — |
| Alpelisib | 8.9% | 97.5% | -88.6% |
| Capivasertib | 8.2% | — | — |
| Osimertinib | 7.9% | — | — |
| Trametinib | 7.9% | — | — |
| Alectinib | 7.9% | — | — |
| Pacritinib | 7.1% | 89.4% | -82.4% |
| Deucravacitinib | 6.7% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.9ms